Figure 2.

The cumulative incidence curves of IS/SE (A), AMI (B), all‐cause mortality (C), ICH (D), major GIB (E), and all major bleeding (F) for patients with nonvalvular AF taking oral anticoagulants before propensity score weighting. Apixaban, rivaroxaban, and dabigatran are associated with reduced risk of IS/SE, ICH, major GIB, all major bleeding, and all cause‐mortality compared with warfarin. AF indicates atrial fibrillation; AMI, acute myocardial infarction; GIB, gastrointestinal bleeding; ICH, intracranial hemorrhage; IS/SE, ischemic stroke/systemic embolism.